Shares of Bionano Genomics (BNGO) experienced a dramatic plunge of 20.73% in Monday's trading session, following an announcement regarding a preliminary payment determination by the Centers for Medicare & Medicaid Services (CMS) for Optical Genome Mapping (OGM). The sharp decline significantly expanded from the 6.44% drop observed in pre-market trading, indicating escalating investor concerns throughout the day.

Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, revealed that CMS had posted the preliminary payment determination for OGM. While specific details of the determination were not provided in the initial announcement, the market's severe negative reaction suggests that investors anticipate potentially unfavorable implications for the company's revenue prospects and the adoption of its key technology.

The magnitude of the stock's decline underscores the critical importance of CMS reimbursement decisions for healthcare technology companies like Bionano Genomics. As OGM is a cornerstone technology for the company, any changes in payment determinations by CMS could significantly impact the adoption and reimbursement of Bionano's products in the healthcare market. Investors are likely to closely monitor further details and the final determination from CMS to reassess the long-term impact on the company's financial outlook and overall business prospects.